Immunomodulatory effects of intravenous immunoglobulins;Effets immunomodulateurs des immunoglobulines intraveineuses

Annales de Medecine Interne

Volumn 151, Issue SUPPL. 1, 2000, Pages

  Kazatchkine, Michel ^a,b   Mouthon, Luc ^a   Kaveri, Srinivas V ^a  

^a INSERM   (France)

^b HÔPITAL BROUSSAIS   (France)

Author keywords

Autoantibodies; Autoimmunity; Immunomodulation; Intravenous immunoglobulins

Indexed keywords

AUTOANTIBODY; COMPLEMENT; CYTOKINE; FC RECEPTOR; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN;

AUTOIMMUNE DISEASE; COMPLEMENT ACTIVATION; DERMATOMYOSITIS; DRUG MECHANISM; GRAFT VERSUS HOST REACTION; GUILLAIN BARRE SYNDROME; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; LYMPHOCYTE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYASTHENIA GRAVIS; POLYNEUROPATHY; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, ANTI-IDIOTYPIC; AUTOIMMUNE DISEASES; COMPLEMENT ACTIVATION; CYTOKINES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; LYMPHOCYTE ACTIVATION; POLYNEUROPATHIES; RECEPTORS, FC;

EID: 0343090774     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. DALAKAS MC. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med, 1997; 126: 721-30.
2. DWYER JM. Manipulating the immune system with immune globulin. N Engl J Med, 1992; 326: 107-16.
3. FEHR JM, HOFMANN V, KAPPELER U. Transient reversal of throbocytopenia in idiopathic thrombocytopenic purpura by high-doses intravenous gammaglobulin. N Engl J Med, 1982; 306: 1254-8.
4. KIMBERLY RP, SALMON JE, BUSSEL JB, KUNTZCROW M, HILGARTNER MW. Modulation of mononuclear phagocyte function by intravenous gamma globulin. J Immunol, 1984; 132: 745-50.
5. CLARKSON SB, BUSSEL JB, KIMBERLY RP, VALINSKY JE, NACHMAN RL, UNKELESS JC. Treatment of refractory immune thrombocytopenic purpura with an anti-Ec gamma-receptor antibody. N Engl J Med, 1986; 314: 1236-9.
6. SALAMA A, MUELLER-ECKHARDT C, KIEFEL V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Competitive inhibition of reticuloendothelial system function by sequestration of autologous red blood cells? Lancet, 1983; ii: 193-5.
7. DEBRÉ M, BONNET MC, FRIDMAN WH, et al. Infusion of Fcy fragments for the treatment of children with acute immune thrombocytopenic purpura. Lancet, 1993; 342: 945-9.
8. BERCHTOLD P, DALE GL, TTANI P, MCMILLAN R. Inibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous immunoglobulins. Blood, 1989; 74: 2414-7.
9. BASTA M, KIRDHBOM P, FRANK MM, FRIES LF. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest, 1989; 84: 1974-81.
10. LIN RY, RACIS SP. In vivo reduction of circulating C1q binding immune complexes by intravenous gammaglobulin administration. Int Arch Allergy Appl Immunol, 1986; 79: 286-90.
11. BASTA M, LANGLOIS PF, MARQUES M, FRANK MM, FRIES LF. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood, 1989; 74: 326-33.
12. BASTA M, DALAKAS MC. High-dose intravenous immunoglobulin exerts its benefiicial effect in patients with dermatomyositis by blocking endomysial deposition of activited complements fragments. J Clin Invest, 1994; 94: 1729-35.
13. ANDERSSON UG, BJORK L, SKANSEN-SAPHIR U, ANDERSON JP. Down-regulation of cytokine production and IL-2 receptor expression by pooled human IgG. Immunology, 1993; 79: 211-6.
14. AMARAN A, RENZ H, LACK G, BRADLEY K, GELFAND EW. Suppression of cytokine-dependant human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol, 1994; 73: 180-6.
15. LING ZD, YEOH E, WEBB BT, FARRELL K, DOUCETTE J, METHESON DS. Intravenous immunoglobulin induces interferon-γand intereuki-6 in vivo. J Clin Immunol, 1993; 13: 302-9.
16. RUIZ-DE-SOUSA V, CARENO MP, KAVERI SV, CAVAILLON JM, KAZATCHKINE MD, HAEFFNER-CAVAILLON N. Slective induction of IL-1 ra and IL-8 in human monocytes by normal polyspecific immunoglobulin G for therapeutic use (IVIg). Eur J Immunol. 1995; 25: 1267-73.
17. AREND WP, SMITH MF, JANSON RW, JOSLIN FG. IL-1 receptor antogonist and IL-1β production in human monocytes and regulated differently. J Immunol, 1991; 147: 1530-6.
18. LEUNG D, KURT-JONES E, NEWBURGER J, COTRAN R, BURN S, PROBER J. Endothelial cell activation of high iinterleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet, 1989; ii: 1298-302.
19. POUTSIAKA DD, CLARK BD, VANNIER E, DINARELLO CA. Production of IL-1 receptor antagonist AND IL-1β by peripheral blood monoclear cells is differentially regulated. Blood, 1991; 78: 1275-9.
20. SHIMOZATO T, IWATA M, KAWADA H, TAMURA N. Human immunoglobulin preparation for iintravenous use inducec elevation of cellular cyclic adenosine 3′ : 5′-monophosphate levels, resulting in suppression of tumor necrosis factor alpha and iinterleukin-1 production. Immunology, 1991; 72: 497-501.
21. AUKRUST P, FROLAND SS, LIABAKK NB, et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood, 1994; 84: 2136-43.
22. ROWLEY AH, GONZALEZ-CRUSSI F, SHULMAN ST. Kawasaki syndrome. Curr Prob Pediatr, 1991; 21: 287-405.
23. SAOUDI A, HUREZ V, DE KOZAK Y, et al. Human immunoglobulin preparations for intravenous use prevent experimental auto-immune uveoretinis. Int Immunol, 1993, 5: 1559-67.
24. PASHOV A, DUBEY C, KAVERI SV, et al. Normal Immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein. Eur J Immol, 1998; 28: 1823-31.
25. NICOLETTI A, KAVERI S, CALIGIURI G, BARIETY J, HANSSON GK. Immunoglobulin treatment reduces atherosclerosis in apo E knackout mice. J Clin Invest, 1998; 102: 910-8.
26. MACH F, SCHONBECK U, SUKHOVA GK, ATKINSON E, LIBBY P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature, 1998; 394: 200-3.
27. ROSSI F, SULTAN Y, KAZATCHKINE MD. Antiidiotypes against autoantibodies and alloantibodies to factor VIII: C (anti-haemophilic factor) arre present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol, 1988; 74: 311-6.
28. ROSSI F, DIETRICH G, KAZATCHKINE MD. Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulatioon of human auto-immune responses. Immunol Rev, 1989; 110: 135-49.
29. VAN DOORM PA, ROSSI F, BRAND A, VAN LINT M, VERMEULEN M, KAZATCHKINE MD. On the mechanism of high dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol, 1990; 29: 57-64.
30. ROSSI F, JAYNE DRW, LOCKWOOD CM, KAZATCHKINE MD. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal polyspecific IgG for theapeutic usqe and in remission sera of patients with systemic vasculitis. Clin Exp Immunol, 1991; 83: 298-303.
31. RONDA N, HAURY M, NOBREGA A, COUTINHO A, KAZATCHKINE MD. Selectivity of recognitioon of variable (V) regions of autoantibodies by intravenous immunoglobulin (IVIg). Clin Immunol Immunopathol, 1994; 70: 124-8.
32. DIETRICH G, PEREIRA P, ALGIMAN M, SULTAN Y, KAZATCHKINE MD. A monoclonal antiidiotypic against the antigen-combining site of anti-factor VIII autoantibodies defines an idiotope that is recognized by normal human polyspecific immunoglobulins for therapeutic use (IVIg). J Autoimmunity, 1990; 3: 547-557.
33. DIETRICH G, KAZATCHKINE MD. Normal immunoglobulin G (IgG) for therapeutic use ties against an immunodominant, disease-associated, cross-reactive idiotype of human antithyroglobulin autoantibodies. J Clin Invest, 1990; 85: 620-5.
34. KAVERI SV, WANG HT, ROWEN D, KAZATCHKINE MD, KOHLER H. Monoclonal anti-idiotypic antibodies against human anti-thyroglubulin autoantibodies recognize idiotopes shared by disease-associated and natural anti-thyroglobulin autoantibodies. Clin Immunol Immunopathol, 1993; 69: 333-40.
35. DWYER DS, BRADLEY RJ, URQUHART CK, KEARNEY JF. Naturally occuring anti-idiotypic antibodies in myasthenia gravis patients. Nature, 1983; 301: 611-4.
36. ZOUALI M, EYQUEM A. Idiotypic/antiidiotypic interactions in systemic lupus erythematosus: demonstration of oscillary levels of DNA autoantibodies and reciprocal antiidiootypic activity in a single patient. Ann Inst Pasteur Immunol, 1983; 1234C: 377-91.
37. SULTAN Y, ROSSI F, KAZATCHKINE MD. Recovery from anti-VIII C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII: C autoantibodies. Proc Natl Acad Sci USA, 1987; 84: 828-31.
38. DIETRICH G, ALGIMAN M, SULTAN Y, NYDEGGER UE, KAZATCHKINE MD. Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg). Blood, 1992; 79: 2946-51.
39. ROUX KH, TANKERSLEY DL. A view of the human idiotypic repertoire: electron microscopic and immunologic analyses of spoontaneous idiotype-anti-idiotype dimers in pooled human IgG. J Immunol, 1990; 144: 1387-95.
40. DIETRICH G, KAVERI SV, KAZATCHKINE MD. A V region-connected autoreactive subfractin of normal human serum immunoglobulin G. Eur J Immunol, 1992; 22: 1701-6.
41. WASSILEV T, GELIN C, KAVERI SV, ZILBER MT, BOUMSELL L, KAZATCHKINE MD. Antibodies to the CD5 molecule in normal human immunoglobulins. IVIg). Clin Exp Immunol, 1993; 92: 369-72.
42. DIETRICH G, VARELA F, HUREZ V, BOUANANI M, KAZATCHKINE MD. Selection of the expressed B cell repertoire by infucion of normal immunoglobulin G in a patient with autoimmune thyroidis. Eur J Immunol, 1993; 23: 2945-50.
43. PRASAD NKA, PAPOFF G, ZEUNEER A, et al. Therapeutic preparations of normal polyspecific iGg (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol, 1998; 767: 3181-90.
44. VIARD I, WEHRLI P, BULLANI R, et al. Inhibition of toxic epidermal necrosis by blockade of CD95 with human intravenous immunoglobulin. Science, 1998; 282: 490-3.
45. MARCHALONIS JJ, KAYMAZ H, DEDEOGLU F, SCHLUTTER SF, YOCUM DE, EDMUNDSON AB. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor β chain. Proc Natl Acad Sci USA, 1992; 89: 3325-9.
46. HUREZ V, KAVERI SV, MOUHOUB A, et al. Anti-CD4 activity of normal human immunoglobulins G for therapeutic use (intravenous immunoglobulin, IVIg). Ther Immunoglobulin, 1994; 1: 269-78.
47. CLAVBERGER C, LYU SC, POULETTY P, KRENSKY AM. Peptides corresponding to T-cell receptor-HLA contact regions inhibit class I-restricted immune responses. Transpl Proc, 1993; 25: 477-8.
48. KAVERI SV, VASSILEV T, HUREZ V, et al. Antibodies to a conserved region of HLA class I molecules, capable of moddulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest, 1996; 97: 865-9.